Prevention of neurological complications during COVID-19: a retrospective analysis of the ISARIC4C national cohort

This study is the first to focus on the prevention of neurological complications and strongly supports the continued use of both dexamethasone and remdesivir in severe COVID-19. Our results suggest that the established benefit of dexamethasone on mortality in COVID-19 is not associated with an increased burden of long-term neurological disability.
Source: Journal of Neurology, Neurosurgery and Psychiatry - Category: Neurosurgery Authors: Tags: Parallel Session 4: COVID Wed 18 May, 1445 - 1600 3 Source Type: research